Background: Anaesthetic neuroprotection in the setting of traumatic brain injury (TBI) remains unproved and is based upon the results in preclinical experiments. Here, we sought to synthesise the results in rodent models of TBI, and to evaluate the effects of publication bias, experimental manipulation, and poor study quality on the effect estimates. Methods: After a systematic review, we used pairwise meta-analysis to estimate the effect of anaesthetics, opioids, and sedativeehypnotics on neurological outcome, and network meta-analysis to compare their relative efficacy. We sought evidence of bias related to selective publication, experimental manipulation, and study quality. Results: Sixteen studies, involving 32 comparisons, were included (546 animals). The treatment improved the neurological outcomes by 35%; 95% confidence interval: 26e44%; P<0.001. The statistical heterogeneity was small (12%), but the 95% prediction interval for the estimate was wide (15e56%). The statistical power was low: 61% (90% confidence interval: 22e86%). The small sample size in the studies was a serious shortcoming reducing the statistical heterogeneity and obscuring differences in outcome between drugs and between experimental conditions. Conclusions: Anaesthetics do provide neuroprotection in rodent models of TBI. The effect-size estimates do not appear to be exaggerated by selective publication, experimental manipulation, or study design. The main shortcoming of the included studies were small sample sizes leading to low power and imprecision, which precluded the network metaanalysis from providing a meaningful ranking for efficacy amongst the drugs. Reliable preclinical investigations of neuroprotection by anaesthetics will require larger sample sizes.
Editor's key points
The authors systematically reviewed the evidence for neuroprotection by the provision of general anaesthesia in traumatic brain injury. Using meta-analytic techniques, the authors examined 16 pre-clinical studies (>500 animals) and found evidence for a reproducible neuroprotective effect, although the included studies tended to use small samples, reducing power and precision.
Evidence to support drug choices for sedation of patients with severe traumatic brain injury (TBI) remains elusive. In a systematic review 1 of a wide variety of agents (ketamine, propofol, etomidate, agents from diverse classes, benzodiazepines, a-2 agonists, and antipsychotics), the authors found no convincing evidence to rank drug efficacy. The authors concluded that clinical trials were urgently needed. The 'bench-to-bedside' research strategy begins with hypothesis testing in preclinical models in vitro and in vivo, 2 leading ultimately to clinical trials. 3 Using rodent models of ischaemic stroke and TBI, 4, 5 successful development of novel treatments has been rare, leading to efforts to improve the quality of preclinical research. 6 Explanations offered for the lack of success include the use of inappropriate animal models, 7 exaggeration of effects by study design flaws, 6 and bias. 8 These features of preclinical research have the potential to generate false-positive results, 9 but we do not know to what extent these criticisms apply to preclinical research in TBI.
Here, we evaluated the results from experimental models of TBI in rats or mice with respect to overall effects of treatment, the comparative efficacy of the study drugs, and sources of bias. We used conventional pairwise meta-analysis with meta-regression and P-curve analysis 10 to identify bias from study factors, selective publication, and data manipulation. We performed a network meta-analysis to compare and rank the effects of individual drugs.
Methods
The research approach and methods were performed according to guidelines for preclinical meta-analysis, 11 prespecified in a study protocol available online. 12 This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for network meta-analysis (PRISMA NMA checklist).
Search strategy
The search strategy for the systematic review was developed by the team librarian (Z.A.P.) with one of the investigators (D.P.A.) and was independently reviewed by a second librarian. 
Inclusion and exclusion criteria
We included abstracts, E-pub, and published articles from 1946 to May 19, 2017 , with no language restriction. For consistency of study design and participants, we limited the range of preclinical models to non-penetrating methods in rats or mice. We excluded studies of brain ischaemia and blast injury because the experimental models are quite different from the non-penetrating models that we did include. We included pharmacological interventions that are frequently administered during the clinical management of TBI: sedativeehypnotics, i.v. or volatile anaesthetics, and opioids. It is not known that the mechanisms by which anaesthetics may exert neuroprotective effects coincide with those by which they exert their clinical effects (anaesthesia, sedation, or analgesia). By including drugs of different classes, we have chosen to emphasise assessment by outcome without any mechanistic restrictions (e.g. see Cipriani and colleagues 13 ). For the meta-analysis, we excluded studies, in which the intervention was delayed more than 1 h after the injury. Studies were excluded if, after contact with the authors, the effect size of the outcome measures could not be expressed as a mean and standard deviation, and when the number of experimental animals could not be determined. We entered the following information into a spreadsheet: reference identification [authors, year of publication, source (journal and abstract), conflict-of-interest statement, and regulatory approval], nature of subjects (species/strain, age, weight, sex), and anaesthetic information [study drug (dose and timing of administration), and control drug or 'awake' controls]. The characteristics of studies are summarised in Supplementary Table S2 . Data were extracted independently in duplicate by D.P.A. and A.M.W. using a standardised pro forma, and verified by S.K.M.
Data handling in meta-analysis
For data handling in the analysis, we converted the neurological outcomes to an effect index: the pooled normalised mean difference [NMD, equation (1)].
We chose this outcome index (instead of the standardised mean difference) for ease of interpretation; the units represent per cent neuroprotection. Neurological outcome scores may be either good or bad, depending on the scoring system; the values were adjusted for the direction of effect. 11 In the network metaanalysis, we compared all treatments to a joint comparator (no treatment or placebo and vehicle were lumped together).
A pairwise meta-analysis of NMD between control and treatment was performed using the inverse variance method NMD ¼ ðmean control À mean shamÞe ðmean treatment À mean shamÞ mean control À mean sham Â 100% (1) for weighting, the DerSimonianeLaird estimator for tau, 2 and the HartungeKnapp adjustment for the random effects model. The similarity of treatment effects amongst the included studies was quantified with the heterogeneity index, I 2 , and tested using the Q statistic with a nominal significance value of P<0.1. The expected range of true effects in similar studies was estimated with the prediction interval. 14 To investigate the potential sources of heterogeneity, we used metaregression to identify effect-size moderators amongst the predefined co-variates. The present analysis involves many small studies and is therefore at risk for overestimating the effect size, because scientific journals may be more likely to publish studies with large effect sizes and studies that achieve nominal statistical significance (P<0.05). Experimental manipulation to achieve statistical significance ('P-hacking') includes data peeking (adding subjects until significance is achieved), selective reporting of data, and exclusion of outliers. 10 We used two tools to identify and correct for these forms of publication bias. To correct for selective reporting of studies with large effect sizes, we constructed a funnel plot and applied the trim-and-fill method. 15 To correct for selective suppression of nonsignificant results and P-hacking, we applied P-curve analysis, which uses the distribution of statistically significant P-values from the included studies to determine whether a true effect is likely to be present 8 (evidential value of the results) and to estimate the size of the effect. 10 The effect size estimated from the P-curve is the anticipated value that would be obtained if the included studies were rerun. 10 Details of the P-curve analysis are provided in Section A4 of the Supplementary data. A pairwise meta-analysis was performed using the metafor Package (version 4.8e4) with R (version 2.0.0). 16 Metaregression and subgroup analyses were performed with the software package Comprehensive Meta-Analysis Version 3 (Englewood, NJ, USA). We used the netmeta package (version 0.9e6) available online at CRAN Project to perform the network meta-analysis. Network geometry was assessed graphically: the netgraph command optimised the distance between nodes (treatments) for direct comparisons using a stress majorisation algorithm. 16 Line width for edges connecting the nodes was proportional to the precision of the estimate of the comparison.
Certain design features of preclinical studies have been reported to bias, that is, to systematically enhance or diminish the observed effect size. Here, we used meta-regression to examine directly the impact of these factors on the observed outcome. We used the risk-of-bias tool developed by the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES score) 6 to evaluate the study risk of bias. In the first step, two investigators (K.J.R. and M.J.H.H.) independently extracted the components of a modified CAMARADES score: (i) monitoring of blood pressure and blood gases, (ii) statement of temperature control, (iii) randomisation to treatment or control group, (iv) allocation concealment, (v) blinded assessment of outcome, (vi) sample-size calculation/power calculation/previous studies, (vii) statement regarding regulatory compliance, and (viii) statement regarding possible conflict of interest. For each of these items, compliance is scored '1', otherwise '0'; a low score indicates increased risk of bias. Omitted from the original score were 'publication in a peer-reviewed journal' (all studies were) and 'avoidance of an anaesthetic with intrinsic neuroprotective activities', resulting in a maximum score of 8.
As the CAMARADES tool has not been validated for TBI, we then used meta-regression of individual components against effect size to identify those categories that were associated with a significant exaggeration or reduction of effect in the present data set. The studies identified as being at risk of bias were then managed in two ways. Firstly, the meta-analysis was repeated excluding the suspect studies to determine to what extent the results were changed. Secondly, compliance in these categories was used to grade the study risk of bias. Using the Cochrane GRADE approach, 17 a study that has characteristics that are associated with biased effect sizes was identified as having a moderate or high risk of bias. If a study was non-compliant in a significant bias item, the risk of bias of that study was downgraded from 'low' to 'moderate'; if the study was non-compliant in two categories, the risk of bias was downgraded from 'moderate' to 'severe'. Using this approach, no results were excluded from the analysis. Concerns about study bias are reflected in the 'level of confidence' in the evidence, calculated using the CINeMA method. 18 The level of agreement amongst the network comparisons (consistency) was evaluated both locally and globally. Local inconsistency was identified by a disagreement between the direct and indirect evidence values for a specific comparison (e.g. isoflurane vs vehicle), generated with the netsplit command in netmeta, and evaluated with a z-test (P<0.1). The presence of a disagreement (local inconsistency) resulted in downgrading the confidence in the evidence in CINeMA. Global consistency (also called incoherence) was assessed with Cochran's Q for the whole network. For network metaanalysis, the included studies must be, in principle, 'jointly randomisable', that is, it is possible to conceive of a large trial that includes all of the treatments (transitivity assumption). Transitivity was assessed by reviewing study designs to ensure that treatments were jointly randomisable. We assessed the level of confidence of the evidence using the Cochrane GRADE approach 17 adapted for network metaanalysis using the online application CINeMA. 18 The number of comparisons in a meta-analysis is represented by k, and the number of animals in a study or study arm is represented by n.
Results are reported as mean values with 95% confidence intervals (CIs). The summary evidence grade for each comparison is indicated by colour coding (high¼green; moderate¼gold; and low¼red) on the forest plot.
Results
The search strategy returned 16 studies for inclusion in the analysis ( Fig. 1 ; Supplementary Table S2 for the characteristics of the studies). The experimental models for TBI in rats or mice were weight reduction, controlled cortical impact, and fluid percussion injury. These techniques are considered to be useful for modelling concussion and diffuse brain injury.
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Sixteen treatments were compared: chloral hydrate, diazepam (two doses), etomidate, fentanyl, halothane (two doses), isoflurane, ketamine, morphine (two doses), pentobarbital, propofol, sevoflurane, vehicle, and xenon. Most comparisons were two armed (12 of 16; 75%), three studies were three armed, and one study had eight arms. The 16 included studies generated 32 pairwise comparisons for neurological outcome and 16 comparisons for lesion volume (Supplementary Table  S4 ). The neurological outcomes were used in the metaanalyses. The included studies generated 56 direct comparisons for the network meta-analysis. Overall, the studies involved 546 animals [345 (63%) rats]. The studies were small: the average group size was 13.
Using the CAMARADES risk-of-bias scoring system (modified, maximum score¼8), a majority of studies (11/16; 69%) were of moderate to high quality [moderate: modified quality score 4e6 (five studies); high quality: score 7e8 (six studies)] ( Table 1 ). The pre-reconciliation inter-rater agreement on the study characteristics was 'substantial'; k (Cohen)¼0.635 (0.508e0.762). Compliance with study design features that mitigate investigator bias 20 was good: randomisation (81%), blinded allocation (63%), blinded assessment (63%), and sample size/power calculation/previous studies (63%). The interrater agreement for the four bias-mitigating study design characteristics was 'high'; the range of k was 0.783e0.922 (probability of random agreement, P<0.001).
Effects of treatment: pairwise meta-analysis
The treated animals had a 35% better neurological outcome than the control animals (95% CI: 26e44%; P<0.001; k¼32; prediction interval: 15e56%). Amongst the predefined sources of bias, only failure to randomise was identified by metaregression as being associated with increased effect. The timing of intervention was negatively correlated with effect size, so including pretreated studies would not inflate the estimate. The CAMARADES score did not have a significant impact on the effect size (P¼0.2164). Excluding the results from the six comparisons that involved non-randomised studies reduced the estimated improvement to 28% (20e37%; P<0.001), which does not change the finding that treatments were associated with improved outcome. The funnel plot (Fig. 2) , which is symmetrical with no studies added by the trim-andfill method, does not support a role for preferential publication of studies with large positive effect sizes. The P-curve analysis showed that the proportion of significant results that are P<0.025 (82%) is greater than that which would be expected if there was no effect (50% of results), indicating that there is evidence of a true effect (Z¼e2.53; P¼0.0057). The statistical power (probability that they will reject the null hypothesis when the null hypothesis is false) of the tests included in the P-curve was low: 61% (90% CI: 22e86%). The effect size estimated from the P-curve was 35% improvement (for details, see Supplementary data A3).
There were many design differences (experimental/methodological heterogeneity) amongst the included studies: species (rats: 24 comparisons; mice: 8 comparisons), timing of intervention relative to TBI (before/during: 24 comparisons; after: 8 comparisons), conditions for the control group (anaesthetised or sedated: 16 comparisons; no treatment, vehicle, saline: 16), study conduct (e.g. allocation concealment and blinding), and the drugs being investigated. The contribution of these factors to the effect size was assessed with Figure 3 . Overall, differences in study design had only a small impact on the variation in effect sizes of the comparisons. The statistical heterogeneity was low; I We used backward stepwise meta-regression to evaluate the potential roles of the predefined study characteristics as effect modifiers and risk of bias: control conditions (anaesthetised vs vehicle), species, injury model, randomisation, blinded allocation, blinded assessment, sample-size calculation, and timing of intervention. Randomisation and timing of intervention were the only significant co-variates (Supplementary Table S5 ). Randomised comparisons (k¼26) were associated with 28% (20e37%) improvement in neurological outcome compared with 63% (44e82%) improvement in non-randomised comparisons (k¼6; P<0.001). Based on the latter finding, lack of randomisation was identified as the only risk factor for bias in the study design category in the GRADE evidence evaluations. A subgroup analysis was performed for timing of treatment (Fig. 3b) because, for human trauma, treatment after an injury is clinically relevant. Drug administration before/during the injury (k¼24) was associated with a 26% (15e37%) improvement compared with 46% (34e57%) (P¼0.017) improvement when treatment followed injury. Considering that the finding that 'before/during' timing tends to decrease rather than exaggerating the effect size, we chose not to downgrade evidence based upon the timing of intervention. Species, injury model, control conditions, and CAMARADES score were not significant co-variates in metaregression (P>0.05). There were no included studies that involved female animals. In the CINeMA application for network GRADE analysis, we set the risk of publication bias for all comparisons in the network at 'undetected'.
meta-regression. A selection of subgroup results is shown in

Network meta-analysis
The studies included in the analysis involved 16 treatments in 17 study 'designs'; the network provided 56 direct pairwise comparisons. Designs were defined by the subset of treatments compared; isoflurane vs vehicle and halothane vs vehicle are two different designs. The evidence graph (Fig. 4) shows that the network is a sparsely connected intersection of two 'star' networks, the principal comparators being vehicle and isoflurane.
Most interventions were associated with an improvement in neurological outcome (Fig. 5) . The exceptions were chloral hydrate, etomidate, morphine (1 mg.kg À1 ), and propofol. The CIs of many of the drugs overlap, showing that the analysis could not distinguish differences related to specific pharmacological characteristics. The 'non-randomised' study design affected four direct treatment comparisons with vehicle: etomidate, diazepam (5 and 10 mg.kg À1 i.p. doses), and morphine (10 mg.kg À1 i.p.). We identified the three non-randomised studies as having a moderate risk of bias: 'some concerns' in the study limitations section of the CINeMA evidence certainty assessment.
Indirectness and transitivity
The included studies were all judged to be relevant to the research question (low indirectness). Review of the designs of the included studies supported compliance with transitivity assumption: we did not find any unique designs; the treatments were jointly randomisable. There were not enough studies to permit direct evaluation of the distribution of potential effect-size moderators, randomisation, and timing of intervention.
Inconsistency (heterogeneity and incoherence)
Overall, the network is coherent: Q global (c 2 )¼14.03, df¼17, P¼0.6652; Q between designs ¼13.59, df¼11, P¼0.2564; and Q within designs ¼0.444, df¼6, P¼0.9985. However, there were seven instances of local incoherence: differences between the direct and indirect estimates out of 40 possible comparisons (18%). The majority of local incoherence (6/7) involved diazepam or etomidate, which received major contributions from nonrandomised studies.
Discussion
Our synthesis of the evidence from rodent models of TBI suggests that many anaesthetics in common use improve neurological outcome in these settings by 30e40%. We did not find evidence that this result is influenced by bias attributable to the study design, selective publication, or experimental manipulation. It is therefore likely the estimates represent true effects and that many of these drugs may confound findings in experiments, in which they are co-administered with specific target agents. The main shortcoming of the included studies, common to many studies in neuroscience, 37 was their small size, which resulted in imprecision and low statistical power. This is evident in the wide prediction interval in the estimate from the pairwise meta-analysis (average observed effect; NMD¼35%; prediction interval¼15e56%). The value of the heterogeneity index, I 2 ¼12%, would suggest low heterogeneity. However, this is due to large sampling errors in the individual studies related to their small sample sizes. I 2 is the proportion of the variance in observed effects that reflects variance in true effects rather than sampling error [equation (2) ]:
where T is the standard deviation of the true effects, and V OBS is the variance of the observed effects. I 2 is, therefore, a relative, not an absolute, measure of heterogeneity. 38 When the sampling error is large, I 2 is small. The heterogeneity in the present studies is more reliably reflected by the prediction interval. 14 The large sampling error and low precision also explain the counter-intuitive result that effect sizes were not sensitive to experimental conditions or drug selection. (When measured in units of metres, there is no difference in average height between grade-school students in Year 1 and Year 3.) Treatment 'during' TBI is unique to the experimental setting. The present data analysis is not adequate to address the role of treatment timing in outcome after experimental TBI, and requires further experiments designed specifically to answer this question.
At a practical level, a research director for a pharmaceutical company, examining the forest plot (Fig. 5) to identify a promising new agent, will find it difficult to define a cut-off to proceed beyond rodent models. If a threshold of 70% improvement is chosen, 39 none of the drugs makes the cut, but 11 of them have 95% CIs that exceed the cut-off. Similar problems occur with most other thresholds. We are not criticising the choice of small groups; simply demonstrating the practical consequences that ensue from the resulting lack of precision. Small sample sizes are common and appropriate in hypothesis-testing research designs that seek 'proof of concept' rather than precise estimation of effect size, thereby limiting the sample size to the minimum predicted by power analysis to achieve nominal statistical significance (P<0.05). For the clinician, the relationship to patient care (translatability) is even more problematic for three reasons. Firstly, in contrast with the standardised experimental models, human TBI is very diverse. Secondly, the lack of physiological support to prevent secondary brain injury in most preclinical study designs is a major departure from clinical practice. Finally, clinical care often requires drug administration for prolonged periods after the original injury. When administered late (!2 h after injury), propofol has been reported to have detrimental, rather than beneficial, effects, 40, 41 suggesting that treatment timing may be critically important. We categorise the level of confidence in the evidence for translatability to human studies as 'very low'. It is likely that many of the drugs in the included studies can influence outcomes, potentially confounding the results of planned experimental interventions. The data are not precise enough to make recommendations about which agents to choose or avoid in preclinical experiments; even though chloral hydrate appears to have little effect, there was only one study informing the estimate. Although the improvement in outcome is probably not sufficient to merit investigation of these drugs as 'treatments', they do provide a degree of neuroprotection. Here, the translatability of the models becomes an issue. To improve precision in future preclinical work in this field, adequately powered studies that are designed to more closely mimic clinical conditions may be financially and logistically feasible if collaboration amongst centres is designed a priori (e.g. multicentre studies or pre-planned network meta-analysis). 
